Condition: Liver Diseases · Sponsor: University Hospital, Basel, Switzerland
To date, no specific treatment options exist for liver diseases, and there is a large global effort to find drugs that will halt liver disease progression in these patients.Liver fibrosis staging is essential as a diagnostic/prognostic measure and there is an increasing demand for accurate non-invasive liver stiffness measurement tools. This research project proposes a novel MR-based quantitative Liver Deformation Biomarker (qLDB) approach for non-invasive liver fibrosis assessment by using a new technique called 4D-MRI. 4D-MRI allows to overcome the limitations of currently used techniques. Hence, 4D-MRI may help to identify a novel biomarker for non-invasive staging of liver fibrosis , and therefore improve the final diagnosis of patients suffering from liver diseases.
This description comes directly from the study's public registry record.
Magdalena Filipowicz Sinnreich, PD Dr. · 0613287789 · magdalena.filipowicz@unibas.ch
Oliver Bieri, Prof. Dr. · 061 556 57 26 · oliver.bieri@unibas.ch
Always discuss trial participation with your own doctor first.
| Kantonsspital Baselland (KSL) | Liestal, Basel-Landschaft, Switzerland | Recruiting |
| University Hospital Basel | Basel, Canton of Basel-City, Switzerland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05385237